Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Early Onset Cataracts > CTX: 30-year study highlights diagnostic and therapeutic advances
  • Early Onset Cataracts

CTX: 30-year study highlights diagnostic and therapeutic advances

Kelsey Moroz

A recent study aimed to analyze the progress and trends in research on cerebrotendinous xanthomatosis (CTX), a rare autosomal recessive disease related to lipid metabolism, over the past 30 years. A total of 561 publications on CTX were analyzed from the Web of Science Core Collection database. Using techniques like keyword clustering and burst detection analysis, researchers pinpointed 3 main hotspots: pathogenesis, diagnosis, and treatment.

Pathogenesis:

  • CTX is caused by mutations in the CYP27A1 gene, impairing sterol 27-hydroxylase, crucial for bile acid synthesis.
  • This leads to metabolic disruptions, including increased bile acid intermediates and a loss of feedback control in cholesterol metabolism.

Diagnosis:

  • Diagnostic tools include clinical assessments, biochemical tests, and genetic evaluations, with neuroimaging (T2-weighted/FLAIR) showing abnormalities in cerebellar white matter.
  • Early diagnosis is essential to prevent neurological decline, but delayed diagnosis is common.
  • New criteria suggest elevated serum cholestanol levels and the presence of CTX symptoms as critical markers.
  • Cataracts are among the earliest and most consistent symptoms of CTX, often appearing before neurological issues. Early detection of cataracts, especially in young patients, can lead to timely diagnosis of CTX and improve treatment outcomes.

Treatment:

  • Chenodeoxycholic acid (CDCA) therapy is the most effective treatment, reducing cholestanol accumulation by inhibiting bile acid production.
  • Long-term studies confirm the safety and efficacy of CDCA in managing CTX.

The study concludes that although significant strides have been made in understanding CTX, challenges in early diagnosis and treatment persist. Future research will likely focus on improving diagnostic tools and therapeutic interventions to address this rare disorder.

Reference
Luo F, Ding Y, Zhang S, et alFrontier and hotspot evolution in cerebrotendinous xanthomatosis: a bibliometric analysis from 1993 to 2023. Sec Neurogenetics. 2024; https://doi.org/10.3389/fneur.2024.1371375

Share

Related Content

  • Early Onset Cataracts

Best of 2025: Surgical timing and long-term considerations in pediatric cataract care

  • Early Onset Cataracts

Quiz: Recognizing CTX in Pediatric Cataract Patients

  • Early Onset Cataracts

Oral sedation shows strong safety profile for office-based cataract surgery

  • Early Onset Cataracts

The importance of pediatric cataract surgery for a variety of patient cases

  • Early Onset Cataracts

Multifocal lenses outperform monofocal implants in pediatric cataract surgery

  • Early Onset Cataracts

When you see cataracts in pediatric patients, genetic testing is important

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon